NASDAQ:AVTX Avalo Therapeutics (AVTX) Stock Price, News & Analysis $11.54 -0.10 (-0.86%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$11.31▼$12.0050-Day Range$10.21▼$13.9052-Week Range$3.95▼$71.04Volume6,670 shsAverage Volume315,711 shsMarket Capitalization$11.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Avalo Therapeutics alerts: Email Address Avalo Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy6.64% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.14Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($28.11) to ($1.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.06 out of 5 starsMedical Sector823rd out of 936 stocksPharmaceutical Preparations Industry383rd out of 436 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Avalo Therapeutics.Read more about Avalo Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.64% of the float of Avalo Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvalo Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avalo Therapeutics has recently decreased by 13.48%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvalo Therapeutics does not currently pay a dividend.Dividend GrowthAvalo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVTX. Previous Next 3.4 News and Social Media Coverage News SentimentAvalo Therapeutics has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Avalo Therapeutics this week, compared to 1 article on an average week.Search Interest5 people have searched for AVTX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avalo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.25% of the stock of Avalo Therapeutics is held by insiders.Percentage Held by Institutions87.06% of the stock of Avalo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Avalo Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Avalo Therapeutics are expected to grow in the coming year, from ($28.11) to ($1.00) per share.Price to Book Value per Share RatioAvalo Therapeutics has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Avalo Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Avalo Therapeutics Stock (NASDAQ:AVTX)Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Read More AVTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVTX Stock News HeadlinesJuly 24 at 10:57 AM | investorplace.comThe 3 Best Personalized Nutrition Stocks to Buy NowJuly 24 at 5:35 AM | americanbankingnews.comAvalo Therapeutics (NASDAQ:AVTX) Shares Down 2.1% July 26, 2024 | Awesomely, LLC (Ad)Automatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…July 16, 2024 | globenewswire.comAvalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical OfficerJuly 9, 2024 | globenewswire.comAvalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis SuppurativaJune 24, 2024 | globenewswire.comAvalo Therapeutics Announces Appointment of Paul Varki as Chief Legal OfficerJune 17, 2024 | globenewswire.comAvalo to Present at the Oppenheimer Novel Targets in Immunology SummitMay 13, 2024 | investorplace.comAVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q1 2024July 26, 2024 | Awesomely, LLC (Ad)Automatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…May 13, 2024 | finanznachrichten.deAvalo Therapeutics: Avalo Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 13, 2024 | globenewswire.comAvalo Reports First Quarter 2024 Financial Results and Provides Business UpdatesApril 17, 2024 | msn.comOppenheimer Upgrades Avalo Therapeutics (AVTX)April 17, 2024 | msn.comAvalo Therapeutics (AVTX) Price Target Increased by 4566.67% to 35.70April 2, 2024 | benzinga.comWhy VirTra Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving PremarketApril 2, 2024 | globenewswire.comAvalo Therapeutics Appoints Biotech Leaders to Board of DirectorsMarch 29, 2024 | marketwatch.comAvalo Therapeutics Shares More than Triple After Co Acquires AlmataBioMarch 29, 2024 | globenewswire.comAvalo Reports 2023 Financial Results and Provides Business UpdatesMarch 29, 2024 | finanznachrichten.deAvalo Therapeutics: Avalo Acquires Anti-IL-1ß mAb and Announces Private Placement Financing of up to $185 MillionSee More Headlines Receive AVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AVTX CUSIPN/A CIK1534120 Webwww.avalotx.com Phone(410) 522-8707FaxN/AEmployees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,540,000.00 Net Margins-1,639.50% Pretax Margin-9,859.63% Return on Equity-1,439.87% Return on Assets-54.17% Debt Debt-to-Equity RatioN/A Current Ratio0.52 Quick Ratio0.52 Sales & Book Value Annual Sales$1.92 million Price / Sales6.28 Cash FlowN/A Price / Cash FlowN/A Book Value$9.11 per share Price / Book1.29Miscellaneous Outstanding Shares1,030,000Free Float1,031,000Market Cap$12.06 million OptionableNot Optionable Beta1.12 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Garry A. Neil M.D. (Age 70)Chairman of the Board, President & CEO Comp: $475kMr. Christopher Ryan Sullivan (Age 40)CFO & Head of Investor relations Comp: $350kDr. Solomon H. Snyder M.D. (Age 85)Founder and Chairman of Scientific Advisory Board Dr. Barbara S. Slusher Ph.D. (Age 59)Founder and Member of Scientific Advisory Board Dr. Lisa Hegg Ph.D.Senior Vice President of Program Management, Corporate Infrastructure & Clinical OperationsMs. Colleen MatkowskiSenior Vice President of Global Regulatory Affairs & Quality AssuranceDr. Dino C. Miano Ph.D.Senior Vice President of CMC & Technical OperationsMore ExecutivesKey CompetitorsVincerx PharmaNASDAQ:VINCGlycoMimeticsNASDAQ:GLYCSol-Gel TechnologiesNASDAQ:SLGLOncoCyteNASDAQ:OCXReneo PharmaceuticalsNASDAQ:RPHMView All CompetitorsInstitutional OwnershipIkarian Capital LLCBought 46,648 shares on 5/17/2024Ownership: 4.511%Affinity Asset Advisors LLCBought 10,000 shares on 5/15/2024Ownership: 0.971%NatixisSold 2,092 shares on 5/14/2024Ownership: 0.244%View All Institutional Transactions AVTX Stock Analysis - Frequently Asked Questions How have AVTX shares performed this year? Avalo Therapeutics' stock was trading at $9.10 at the start of the year. Since then, AVTX stock has increased by 26.8% and is now trading at $11.54. View the best growth stocks for 2024 here. How were Avalo Therapeutics' earnings last quarter? Avalo Therapeutics, Inc. (NASDAQ:AVTX) released its quarterly earnings data on Monday, May, 13th. The company reported ($5.98) earnings per share for the quarter, missing analysts' consensus estimates of ($1.18) by $4.80. Avalo Therapeutics had a negative trailing twelve-month return on equity of 1,439.87% and a negative net margin of 1,639.50%. When did Avalo Therapeutics' stock split? Avalo Therapeutics's stock reverse split on the morning of Friday, December 29th 2023. The 1-240 reverse split was announced on Friday, December 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. How do I buy shares of Avalo Therapeutics? Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVTX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTX Stock Alerts